ASPG and acute lymphoblastic leukemia: Pediatric-inspired regimens for adolescent and young adult (AYA) patients with ALL, which contain either L-asparaginase or pegylated (peg)-asparaginase, have been demonstrated to improve disease responses and survival outcomes, and are now considered standard treatment for this age group, which includes patients 15–39 years of age per the National Comprehensive Cancer Network (PA, USA) AYA definition [6–9].